News

Article

FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma

Author(s):

Key Takeaways

  • The FDA lifted the partial clinical hold on the TakeAim Lymphoma study evaluating emavusertib in lymphoma patients.
  • The study aims to determine safety, maximum tolerated dose, and activity signals of emavusertib alone and with Imbruvica.
SHOW MORE

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

The Food and Drug Administration (FDA) has lifted their partial clinical trial hold on a study evaluating the inhibitor emavusertib in patients with lymphoma.

The goals of the phase 1/2 TakeAim Lymphoma study are to determine safety, maximum tolerated dose, signals of activity and the recommended dose of emavusertib for future studies, for patients with relapsed/refractory non-Hodgkin Lymphoma, Waldenström macroglobulinemia, lymphoplasmacytic lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. according to a press release from the manufacturer of the drug, Curis. This current study will also focus on dose escalation and expansion in emavusertib alone and in combination with Imbruvica (ibrutinib).

"We are excited to announce that (the) FDA has completed its review of the TakeAim Lymphoma study and has lifted the partial clinical hold,” said James Dentzer, president and CEO of Curis, in the release. “We are working with our clinical sites to quickly resume enrollment of new patients in this study in the third quarter."

The partial hold, which was originally placed by the FDA in April of this year, was lifted after an agreement on Curis’ strategy to identify and manage patients who developed rhabdomyolysis (a medical condition which occurs when damaged muscle tissue release proteins and electrolytes into the blood and can result in permanent disability).

The agreement also states that researchers in the trial enroll at least nine additional patients receiving 200 milligrams of emavusertib in combination with Imbruvica.

In particular, emavusertib is an inhibitor that targets certain receptors often dysregulated in patients with cancer, according to the release. Emavusertib may target a long-form genetic expression present in approximately half of patients with acute myeloid leukemia and myelodysplastic syndrome.

Curis plans to release updated data from this study in 2023, according to the statement. The manufacturer is also discussing future clinical trial plans for emavusertib such as an optimal dose.

Of note, a separate partial hold was also placed on the TakeAim Leukemia study but has not been lifted at this time. The press release did not state reasons for either study’s partial hold.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of doctor with text.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.